CIDP Spectrum: Chronic Immune-Mediated Demyelinating Neuropathies
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable immune-mediated neuropathy with an incidence of 1.6 per 100,000 per year and a prevalence of 8.9 per 100,000. The clinical spectrum encompasses typical CIDP, several phenotypic variants, and related conditions including multifocal motor neuropathy (MMN) and autoimmune nodopathies. Accurate diagnosis is critical because overlapping clinical features among chronic demyelinating neuropathies require careful attention to symptom evolution, examination findings, and supportive data — misdiagnosis rates approach 50% in some series, resulting in potentially harmful treatments.
Bottom Line
- Typical CIDP: Accounts for 50–60% of all CIDP cases; presents with symmetric proximal and distal weakness and sensory loss in ≥2 limbs with areflexia, progressing over >2 months
- EAN/PNS 2021 criteria: Optimal sensitivity (81–88%) and specificity (86–97%) achieved when ≥4 motor and ≥4 sensory nerves are tested on electrodiagnostic studies
- CIDP variants: Include distal, multifocal (MADSAM/Lewis-Sumner), focal, motor, and sensory phenotypes — approximately 50% evolve to a more typical pattern over time
- Acute-onset CIDP: Up to 16% of CIDP patients present acutely, mimicking GBS; progression beyond 8 weeks or >3 treatment-related fluctuations favors CIDP
- Autoimmune nodopathies: Approximately 10% of patients meeting CIDP electrodiagnostic criteria have antibodies against paranodal/nodal proteins (NF155, NF186, CNTN1, CASPR1); these respond poorly to standard treatments but may respond to rituximab
- MMN: Asymmetric, distal, upper limb-predominant pure motor weakness with conduction block; anti-GM1 antibodies present in 30–80%; responds to IVIg but NOT corticosteroids
- First-line treatment: IVIg, corticosteroids, or plasma exchange for induction and maintenance; subcutaneous immunoglobulin for maintenance; 80–90% of patients improve with first-line therapy
Typical CIDP: Clinical and Electrophysiologic Features
The typical clinical phenotype of CIDP presents with symmetric proximal and distal upper and lower extremity weakness and sensory loss affecting at least two limbs with areflexia that progresses over a period greater than 2 months. The course can be relapsing with intermittent recurrence of symptoms, monophasic, or progressive. The underlying pathophysiology involves both humoral and cellular immune-mediated mechanisms, including T-cell dysregulation with impaired suppressive capacity of regulatory T cells, upregulation of inflammatory T cells and cytokines, increased macrophage activation, and complement-dependent processes.
EAN/PNS 2021 Electrodiagnostic Criteria
The 2021 European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) guidelines updated the diagnostic criteria for CIDP. Two 2022 validation studies demonstrated that these criteria are roughly equivalent to the earlier 2010 EFNS/PNS criteria and tend to improve diagnostic accuracy for CIDP variants.
| Criterion | Strongly Supportive of Demyelination (must meet in ≥2 nerves) |
|---|---|
| Motor distal latency | Prolongation ≥50% above ULN in 2 nerves (excluding median at wrist from CTS) |
| Motor conduction velocity | Reduction ≥30% below LLN in 2 nerves |
| F-wave latency | Prolongation ≥20% above ULN in 2 nerves (≥50% if distal CMAP amplitude <80% LLN) |
| F-wave absence | In 2 nerves (if distal CMAP ≥20% LLN) + ≥1 other demyelinating parameter in ≥1 other nerve |
| Conduction block | ≥30% proximal-to-distal CMAP amplitude reduction (excluding tibial nerve); distal CMAP ≥20% LLN |
| Temporal dispersion | ≥30% duration increase between proximal and distal CMAP (≥100% in tibial nerve) in ≥2 nerves |
| Distal CMAP duration | Prolongation in ≥1 nerve + ≥1 other demyelinating parameter in ≥1 other nerve |
Weakly supportive: Meeting any of the above criteria in only one nerve. The recommended minimum study includes median, ulnar (stimulated below the elbow), peroneal (stimulated below the fibular head), and tibial nerves on one side. Conduction block or slowing is not considered at the ulnar nerve across the elbow or the peroneal nerve across the knee.
Acute-Onset and Subacute-Onset CIDP
Up to 16% of patients present with acute or subacute CIDP, making the distinction from Guillain-Barré syndrome (GBS) challenging. GBS is a monophasic acute demyelinating neuropathy that reaches nadir within 4 to 8 weeks. If symptoms continue to relapse with greater than three treatment-related fluctuations or continue to progress beyond 8 weeks, the more likely diagnosis is CIDP.
Distinguishing Acute-Onset CIDP from GBS
- Favoring GBS: Preceding infection, autonomic dysfunction, respiratory compromise, bifacial weakness, monophasic course reaching nadir within 4–8 weeks
- Favoring CIDP: Progression beyond 8 weeks, relapsing course with >3 treatment-related fluctuations, absence of preceding infection or autonomic features
- Clinical monitoring: Serial assessment over time is required to establish the correct diagnosis
CIDP Variants
CIDP has several clinical phenotypic variants characterized by asymmetric, purely motor, purely sensory, focal, or distally patterned motor and sensory findings. Approximately 50% of the variants phenotypically change over time to a more typical pattern of weakness.
| Variant | Clinical Features | Examination Findings | Electrodiagnostic Pattern |
|---|---|---|---|
| Distal | Distal sensory loss and weakness, predominantly lower limbs | Distal sensory loss (upper and lower), weakness worse in lower limbs, distally absent or reduced reflexes | Demyelinating features in motor and sensory nerves |
| Multifocal (MADSAM/Lewis-Sumner) | Asymmetric weakness and sensory changes | Asymmetric weakness, sensory loss, reflexes may be normal in unaffected limbs | Multifocal demyelination in motor and sensory nerves |
| Focal | Symptoms localizable to one limb | Weakness and sensory changes in one limb | Demyelinating features restricted to the affected limb |
| Motor | Symmetric distal and proximal motor symptoms | Motor weakness, normal sensation, reduced or absent reflexes | Generalized motor demyelination; sensory fibers often spared |
| Sensory | Symmetric distal and proximal sensory symptoms | Diffusely reduced/absent reflexes, normal motor strength | Prolonged somatosensory evoked potential latencies; motor responses generally normal |
Distal CIDP
Distal CIDP presents with symmetric sensory loss and distal weakness in the upper and lower extremities along with gait abnormality. Approximately two-thirds of patients with this phenotype have an IgM paraprotein. Anti-myelin-associated glycoprotein (MAG) antibodies should be tested in this clinical phenotype because anti-MAG neuropathy is not considered CIDP but has similar clinical features. Patients with distal CIDP without monoclonal proteins and without anti-MAG antibodies tend to respond to typical first-line CIDP treatments.
Multifocal CIDP (MADSAM / Lewis-Sumner Syndrome)
Multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), also known as Lewis-Sumner syndrome, presents with asymmetric weakness and sensory loss affecting the upper or lower extremities. The key distinguishing feature from MMN is the clinical combination of motor and sensory symptoms with correlative multifocal demyelinating electrophysiologic changes in both motor and sensory nerves. This distinction is clinically important because multifocal CIDP responds to corticosteroids or IVIg, whereas MMN does not respond to corticosteroids and may worsen with steroid treatment.
Motor and Sensory CIDP
Motor CIDP presents with only motor weakness in a proximal and distal pattern with reduced reflexes and no sensory symptoms. If sensory nerve conduction studies are abnormal in clinically motor CIDP, the diagnosis is motor-predominant CIDP. Notably, motor-predominant CIDP can worsen with steroid treatment. Sensory CIDP is rare (5–15% of CIDP patients) with pure sensory symptoms and absent or reduced reflexes. If motor nerve conduction studies demonstrate conduction block or conduction velocity slowing without clinical motor weakness, the diagnosis is sensory-predominant CIDP.
Chronic Immune Sensory Polyradiculopathy (CISP)
- Patients with clinically sensory CIDP who have normal motor and sensory nerve conduction studies may have CISP
- Somatosensory evoked potentials are often abnormal due to involvement of sensory roots proximal to the dorsal root ganglia
- Thought to be autoimmune in nature but was not classified as a CIDP variant in the EAN/PNS guidelines
Multifocal Motor Neuropathy
MMN, although not technically a CIDP variant, is an immune-mediated chronic demyelinating neuropathy with distinct clinical and therapeutic implications. The presentation is asymmetric, distal, upper limb-predominant with pure motor symptoms. Finger flexors are relatively spared, and foot drop may be the first symptom in one-third of patients. There is a male predominance with a mean age of onset around 40 years. Fasciculations and cramps are reported in approximately 40% of patients.
| Feature | Details |
|---|---|
| Distribution | Asymmetric, distal, upper limb-predominant |
| Symptoms | Pure motor weakness; no sensory loss |
| Anti-GM1 antibodies | Present in 30–80% of patients; absence does not exclude the diagnosis |
| Electrodiagnosis | Motor nerve conduction block + demyelinating features; normal sensory responses |
| Diagnosis requires | Motor nerve involvement in ≥2 nerves for >1 month |
| Treatment | IVIg (first-line); can transition to SCIg for maintenance |
| Corticosteroids | Do NOT help and may worsen symptoms |
MMN: Critical Distinctions
- If any signs of sensory loss, upper motor neuron dysfunction, bulbar involvement, or symmetric weakness are present, consider an alternative diagnosis
- Conduction block may be difficult to detect if very proximal or distal
- Corticosteroids either do not help or can worsen symptoms — use IVIg only
- Dosing and interval must be monitored to prevent axonal loss, which can lead to irreversible cumulative disability
Autoimmune Nodopathies and Paranodopathies
Approximately 10% of patients meeting CIDP electrodiagnostic criteria have antibodies against node of Ranvier nodal and paranodal proteins. This population is of particular interest because it differentiates a group of patients who respond differently to standard treatments. Targets include nodal neurofascin 186 (NF186) or paranodal proteins contactin-1 (CNTN1), contactin-associated protein 1 (CASPR1), or neurofascin 155 (NF155). The majority reflect an IgG4-mediated response.
Clinical Phenotype of Autoimmune Nodopathies
- Demographics: More likely adults, male predominance
- Presentation: Severe, symmetric, distal, motor-predominant, rapidly progressive disease
- Distinctive features: Low-frequency tremor and sensory ataxia more prominent than in typical CIDP
- CNTN1 antibodies: Associated with nephrotic syndrome
- Panneurofascin antibodies: Associated with underlying lymphoma, myeloma, and leukemia
- Treatment response: Partial or no response to IVIg, plasma exchange, or corticosteroids; rituximab is the treatment of choice
- CSF protein: Often markedly elevated
Case Illustration: Anti-NF155 Nodopathy
A 25-year-old man presented with 5 months of progressive painless weakness, hand tremor, and ataxia. Examination revealed proximal and distal weakness, absent reflexes, and distal sensory loss. A prominent low-frequency, high-amplitude action tremor with postural and intention components was noted. Electrodiagnostics met CIDP criteria with multiple conduction blocks. Despite IVIg loading (2 g/kg) and corticosteroids (40 mg/day), only partial improvement was achieved after 6 months. CSF protein was markedly elevated at 435 mg/dL with albuminocytologic dissociation. Anti-NF155 antibodies were detected. After rituximab (two 1000-mg infusions separated by 2 weeks), significant improvement occurred within 3 months, allowing tapering of IVIg and steroids.
Teaching point: Young onset, tremor, ataxia, and partial/no response to first-line therapies should prompt testing for antinodal and paranodal antibodies. Rituximab can be highly effective in this population.
CANOMAD
Chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins, and disialosyl antibodies (CANOMAD) is a rare chronic demyelinating neuropathy presenting with ocular and bulbar weakness, sensory ataxia, paresthesias or hypoesthesia, and serum monoclonal IgM gammopathy. Electrophysiologic studies demonstrate a demyelinating or axonal pattern. The condition results in moderate disability.
Supportive Diagnostic Testing
Several tests can support the diagnosis of CIDP when the diagnosis is possible but not definitive. None should be used in isolation. The EAN/PNS guidelines recommend that an objective response to one of the first-line therapies is considered supportive of the clinical diagnosis — approximately 80–90% of patients show improvement with first-line treatment.
CSF Analysis
CIDP is characterized by albuminocytologic dissociation — a normal nucleated cell count with elevated protein levels. CSF protein >100 mg/dL provides strong evidence supporting the diagnosis. CSF pleocytosis >10 cells/mm³ (and particularly >50 cells/mm³) should raise suspicion for an infectious or malignant etiology. In patients older than 50 years, CSF protein between 45 and 60 mg/dL should be interpreted with caution and should not be used as the sole supportive test.
Imaging
| Modality | Supportive Findings | Important Caveats |
|---|---|---|
| MRI (cervical/lumbar spine, plexus) | Focal nerve enlargement, hyperintensity, or enhancement of nerve roots | Not specific to CIDP; also seen in hereditary neuropathy, amyloidosis, CMT, paraprotein-related neuropathies, neurofibromatosis, diabetic radiculoplexus neuropathies, leprosy, MMN, and neurolymphomatosis |
| Ultrasound | Nerve enlargement (cross-sectional area) in ≥2 sites in proximal median nerve segments or brachial plexus | Median nerve CSA must exceed specific thresholds: >10 mm² at forearm, >13 mm² in upper arm, >9 mm² at trunk, >12 mm² at nerve roots. Prone to the same mimics as MRI |
Nerve Biopsy
Because of associated morbidity and poor sensitivity and specificity, nerve biopsy is not routinely performed. Findings that would support the diagnosis include thinly myelinated axons and onion bulb formation, demyelinating features on teased fiber preparations and electron microscopy, or perivascular macrophage infiltration. Biopsies should be performed only at centers with experienced surgeons and pathologists.
Outcome Measures
Objective improvement should be documented on at least one measure of disability and one impairment scale to support the diagnosis, particularly in cases of possible CIDP.
| Outcome Measure | Guide for Meaningful Change |
|---|---|
| I-RODS (Inflammatory Rasch-built Overall Disability Scale) | ≥4-centile metric score change |
| INCAT disability scale | ≥1 point |
| Modified INCAT Sum Score | ≥2 points |
| MRC Sum Score (0–60) | ≥2–4 points |
| Grip strength (vigorimeter) | ≥8–14 kPa |
| Grip strength (hand dynamometer) | ≥10% |
Treatment
First-Line Therapies for CIDP and Variants
Treatment of typical CIDP and its variants includes IVIg, corticosteroids, or plasma exchange as first-line induction and maintenance therapies. Subcutaneous immunoglobulin (SCIg) is considered a first-line maintenance treatment. Selection depends on patient comorbidities, cost, accessibility, and risk-benefit profile. Approximately 80–90% of patients show improvement with first-line treatment within the first 3 to 6 months.
| Treatment | Induction Regimen | Maintenance | Key Considerations |
|---|---|---|---|
| IVIg | 2 g/kg over 4–5 days, then 1 g/kg every 3–4 weeks × 2–5 doses | 1 g/kg every 3–4 weeks; extend interval or reduce dose once stable | Adverse effects: aseptic meningitis, PE/DVT risk, headache. Taper every 6–12 months in first 2–3 years, then every 1–2 years |
| SCIg | Not typically used for induction | 1:1 dose transition from IVIg (e.g., 80 g IVIg q4wk → 20 g SCIg weekly); may need upward adjustment | Patient preference, venous access limitations, or side effect profile may drive the transition |
| Corticosteroids | Oral prednisone 20–60 mg/day, OR IV methylprednisolone 1000 mg/day × 3–5 days | Taper after plateau of improvement | Avoid in motor-predominant CIDP and MMN (can worsen symptoms). Consider patient preference regarding oral vs. IV route |
| Plasma exchange | 5 exchanges every other day over 2 weeks (typically requires hospitalization) | Frequency as needed; limited by venous access | Practical limitations: requires good venous access; long-term maintenance challenging due to catheter complications |
Second-Line and Refractory CIDP
If individual therapies or combination therapy with immunoglobulin and steroids is not effective, steroid-sparing agents can be considered. Azathioprine, mycophenolate mofetil, or cyclosporine can be used for maintenance, although no strong evidence has shown that these medications effectively reduce the need for steroid or immunoglobulin dosing. For patients with a clear diagnosis of CIDP who have no response to first-line treatment, cyclophosphamide or rituximab can be used.
Treatment of Specific Subtypes
Treatment by Subtype
- Autoimmune nodopathies (NF155, NF186, CNTN1, CASPR1): Often partial or no response to IVIg, plasma exchange, or steroids. Rituximab is the treatment of choice — standard dosing (two 1000-mg infusions 2 weeks apart) or low-dose protocol (100 mg weekly × 4 weeks, then 100 mg monthly × 2 months). Response occurs weeks to months after initiation and can be sustained 1–2 years
- MMN: IVIg is the only proven first-line treatment; can transition to SCIg. Cyclophosphamide may be used with caution. Corticosteroids are contraindicated
- Anti-MAG neuropathy: Limited evidence for treatment efficacy. For mild disease, symptomatic treatment. For severe disability or rapid decline, consider IVIg, plasma exchange, or rituximab (improves symptoms in 30–50%)
Case Illustration: Switching First-Line Therapy
A 56-year-old man presented with 3 months of progressive proximal and distal weakness with distal sensory loss. Electrodiagnostics met EAN/PNS criteria definitively. Given the definitive clinical and electrodiagnostic confirmation, no additional supportive testing was needed. He was started on IVIg loading (2 g/kg over 5 days) but developed a pulmonary embolism one week later. He was switched to pulse-dose IV methylprednisolone (1000 mg daily × 3 days induction, then 1000 mg monthly maintenance), chosen over daily oral steroids based on patient preference.
Teaching point: When the diagnosis is definitive by clinical and electrodiagnostic criteria, additional supportive testing is unnecessary. In the case of adverse reactions to one first-line therapy, an alternative first-line option should be started. Patient preference for route of treatment influences adherence and treatment success.
Red Flags for Alternative Diagnoses
Up to one-half of patients initially diagnosed with CIDP may ultimately be found to have an alternative diagnosis. Diseases misdiagnosed as CIDP include inherited neuropathies (CMT, hereditary amyloidosis), MMN, motor neuron disease, idiopathic axonal neuropathy, and small fiber neuropathy.
| CIDP Phenotype | Clinical Red Flags | Laboratory Red Flags |
|---|---|---|
| Typical CIDP | Subacute onset with low-frequency tremor, marked ataxia, distal predominance (autoimmune nodopathy); autonomic features or pain (ATTRv, diabetic neuropathy) | Elevated glucose/HbA1c (diabetic); IgA/IgG gammopathy (myeloma, AL amyloidosis, POEMS); IgM gammopathy (anti-MAG) |
| Distal CIDP | Family history (CMT or ATTRv amyloidosis) | Elevated glucose/HbA1c; IgA/IgG gammopathy (POEMS, myeloma); IgM gammopathy (anti-MAG) |
| Multifocal/Focal CIDP | Pain (diabetic radiculoplexopathy, neuralgic amyotrophy); normal sensation (MMN); single nerve in single limb (entrapment/tumor); family history (HNPP) | ANA/ANCA positive (vasculitic neuropathy) |
| Motor CIDP | Dyspnea, dysarthria, dysphagia (motor neuron disease, myasthenia gravis) | Elevated serum CK (inflammatory myopathy) |
| Sensory CIDP | Idiopathic sensory axonal neuropathy; family history (hereditary sensory neuropathy) | Elevated glucose/HbA1c; low B12; IgM gammopathy (anti-MAG); normal motor/sensory studies (CISP) |
Key Mimics to Exclude
- POEMS syndrome: Uniformly demyelinating without conduction block; pain more prominent than in CIDP; mandatory criteria include polyneuropathy + lambda monoclonal protein; check VEGF level (may be artificially lowered by immunosuppressive treatment)
- Anti-MAG neuropathy: Distal predominant slowing with pronounced distal latency prolongation; >50% of patients with distal demyelinating neuropathy + IgM gammopathy develop anti-MAG antibodies
- Hereditary neuropathies (CMT1): Uniform conduction velocity slowing without conduction block or temporal dispersion; family history; genetic testing confirms
- Hereditary amyloidosis (ATTRv): Pain, dysautonomia, cardiac/GI involvement; axonal pattern with mild-to-moderate CV slowing mimicking CIDP
Monitoring and Prognosis
It is recommended to set expectations for prognosis and degree of improvement before or at initiation of treatment. Patients should understand the concept of a wearing-off effect between treatment doses, which typically involves some degree of worsening of functional impairment or disability. Improvement is expected within the first 3 to 6 months of treatment. Tapering of immunoglobulin should be attempted approximately every 6 to 12 months once clinical stability is achieved in the first 2 to 3 years, and then every 1 to 2 years thereafter. Outcome measures such as grip strength, I-RODS, and INCAT scores should be assessed approximately every 3 months to guide treatment decisions regarding dose reduction or interval extension.
Monitoring Checklist
- Assess disability (I-RODS or INCAT) and impairment (MRC sum score, grip strength) at baseline and every 3 months
- If no improvement after 3–6 months on first-line therapy, reconsider the diagnosis or adjust treatment
- Monitor for wearing-off symptoms before the next treatment dose
- Average outcome measures over at least 3 days to improve specificity
- Consider antinodal/paranodal antibody testing in refractory cases
- Attempt treatment taper every 6–12 months in the first 2–3 years, then every 1–2 years
References
- Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force — second revision. J Peripher Nerv Syst. 2021;26(3):242–268.
- Laughlin RS, Dyck PJ, Melton LJ, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73(1):39–45.
- Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784–794.
- Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019;90(2):125–132.
- Rajabally YA, Afzal S, Loo LK, Goedee HS. Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2022;93(12):1247–1252.
- Doneddu PE, De Lorenzo A, Manganelli F, et al. Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2022;93(12):1239–1246.
- Allen JA. The misdiagnosis of CIDP: a review. Neurol Ther. 2020;9(1):43–54.
- Cortese A, Lombardi R, Briani C, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflammation. 2020;7(1):e639.
- Querol L, Devaux J, Rojas-Garcia R, Illa I. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017;13(9):533–547.
- Yeh WZ, Dyck PJ, van den Berg LH, et al. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry. 2020;91(2):140–148.
- Lawson VH, Arnold WD. Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr Dis Treat. 2014;10:567–576.
- Garcia-Santibanez R, Zaidman CM, Sommerville RB, et al. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). J Neurol. 2018;265(6):1402–1409.
- Querol L, Rojas-Garcia R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflammation. 2015;2(5):e149.
- Jiao L, Xiang Y, Li S, et al. Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155. J Neuroimmunol. 2020;345:577280.
- Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–144.
- Allen JA, Merkies ISJ, Lewis RA. Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care: a review of clinical and laboratory assessment measures. JAMA Neurol. 2020;77(9):1159–1166.
- Sinnreich M, Klein CJ, Daube JR, et al. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology. 2004;63(9):1662–1669.
- Dziadkowiak E, Waliszewska-Prosol M, Nowakowska-Kotas M, et al. Pathophysiology of the different clinical phenotypes of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Int J Mol Sci. 2021;23(1):179.
- Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(7):812–827.
- van Lieverloo GGA, Peric S, Doneddu PE, et al. Corticosteroids in chronic inflammatory demyelinating polyneuropathy: a retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol. 2018;265(9):2052–2059.
- Breiner A, Bourque PR, Allen JA. Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. Muscle Nerve. 2019;60(2):180–183.
- Dimachkie MM, Barohn RJ, Katz J. Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy and other chronic acquired demyelinating polyneuropathy variants. Neurol Clin. 2013;31(2):533–555.
- Querol LA, Hartung HP, Lewis RA, et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies. Neurother J Am Soc Exp Neurother. 2022;19(3):864–873.
- Fehmi J, Vale T, Keddie S, Rinaldi S. Nodal and paranodal antibody-associated neuropathies. Pract Neurol. doi:10.1136/practneurol-2021-002960.
- Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17(2):289–294.